Insider Selling: Exact Sciences Corporation (NASDAQ:EXAS) Insider Sells 45,775 Shares of Stock

Exact Sciences Corporation (NASDAQ:EXAS) insider Graham Peter Lidgard sold 45,775 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $53.60, for a total value of $2,453,540.00. Following the sale, the insider now directly owns 272,819 shares of the company’s stock, valued at $14,623,098.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Graham Peter Lidgard also recently made the following trade(s):

  • On Monday, October 2nd, Graham Peter Lidgard sold 81,025 shares of Exact Sciences Corporation stock. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00.
  • On Tuesday, September 5th, Graham Peter Lidgard sold 75,683 shares of Exact Sciences Corporation stock. The stock was sold at an average price of $40.81, for a total value of $3,088,623.23.
  • On Friday, September 1st, Graham Peter Lidgard sold 45,775 shares of Exact Sciences Corporation stock. The stock was sold at an average price of $41.49, for a total transaction of $1,899,204.75.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) traded up $0.88 during trading on Tuesday, reaching $59.74. The company’s stock had a trading volume of 1,066,720 shares, compared to its average volume of 2,519,588. Exact Sciences Corporation has a fifty-two week low of $13.05 and a fifty-two week high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company’s quarterly revenue was up 158.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.36) EPS. sell-side analysts forecast that Exact Sciences Corporation will post -1.12 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/11/21/insider-selling-exact-sciences-corporation-exas-insider-sells-2453540-00-in-stock.html.

A number of hedge funds have recently bought and sold shares of EXAS. Fortaleza Asset Management Inc. bought a new position in Exact Sciences Corporation during the 2nd quarter worth $106,000. Krilogy Financial LLC increased its position in Exact Sciences Corporation by 1,460.0% during the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after buying an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Exact Sciences Corporation by 17.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after buying an additional 600 shares during the period. Oppenheimer Asset Management Inc. increased its position in Exact Sciences Corporation by 2,925.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after buying an additional 3,072 shares during the period. Finally, Financial Architects Inc increased its position in shares of Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after purchasing an additional 2,035 shares during the period. Hedge funds and other institutional investors own 86.04% of the company’s stock.

Several brokerages have recently weighed in on EXAS. Zacks Investment Research cut shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Benchmark Co. reaffirmed a “buy” rating and set a $60.00 price target (up from $50.00) on shares of Exact Sciences Corporation in a research note on Tuesday, October 31st. Vetr raised shares of Exact Sciences Corporation from a “sell” rating to a “buy” rating and set a $41.07 price target for the company in a research note on Wednesday, August 2nd. Leerink Swann reaffirmed an “outperform” rating and set a $50.00 price target (up from $45.00) on shares of Exact Sciences Corporation in a research note on Thursday, September 21st. Finally, Bank of America Corporation raised their price target on shares of Exact Sciences Corporation from $56.00 to $58.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Eight research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $49.98.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply